
Trelegy Ellipta and health-related quality of life (HRQoL)
Single-inhaler Triple Therapy could help your COPD patients breathe better from today1,2

COPD can make activities such as attending social events with friends or playing with their grandchildren more difficult, impacting quality of life3

TRELEGY Ellipta: Statistically superior improvement vs. budesonide/formoterol in HRQoL1

TRELEGY Ellipta: Statistically superior improvement vs. a LAMA/LABA (UMEC/VI) in HRQoL2
Statistically superior improvement in HRQoL vs. budesonide/formoterol1

Adapted from Lipson et al. 20171
HRQoL determined according to the St. George's Respiratory Questionnaire (SGRQ). Find out more lower down this page. SGRQ MCID=4.0 unit change
The figures have been rounded from -6.57 and -4.33, respectively
Data from the FULFIL study comparing TRELEGY Ellipta OD to BUD/FOR.1 Co-primary endpoints of change from baseline in trough FEV1 and SGRQ score at Week 24 were both met
Statistically superior improvement in HRQoL vs. a LAMA/LABA (UMEC/VI)2

Adapted from Lipson et al. 20182
HRQoL determined according to the St. George's Respiratory Questionnaire (SGRQ). Find out more lower down this page. SGRQ MCID=4.0 unit change
Data from the IMPACT trial comparing TRELEGY Ellipta OD to an ICS/LABA (FF/VI) and a LAMA/LABA (UMEC/VI).2 Co-primary endpoints of annual rate of on-treatment moderate/severe exacerbations for TRELEGY Ellipta vs. both comparators were met. Change from baseline in SGRQ score at Week 52 was a secondary endpoint
Key trial design
Get started with Trelegy Ellipta
Footnotes
BD, twice daily; BUD, budesonide; CAT, COPD assessment test; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; HRQoL, health-related quality of life; ICS, inhaled corticosteroid; LABA, long- acting ß2-agonist; LAMA, long-acting muscarinic antagonist; LS, least squares; MCID, minimal clinically important difference; OD, once daily; UMEC, umeclidinium; VI, vilanterol
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA4
References
- Lipson DA et al. Am J Crit Care Med 2017; 196:438–446
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
- Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD). 2024.
- TRELEGY Ellipta SmPC. Available at www.medicines.ie. Accessed April 2024.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trelegy is a registered trademark of the GlaxoSmithKline group of companies.
TRELEGY Ellipta was developed in collaboration with

Last Updated: April 2024 PM-IE-FVU-WCNT-240003